Results 241 to 250 of about 2,243,647 (283)

CHK1 inhibition overcomes gemcitabine resistance in non-small cell lung cancer cell A549. [PDF]

Mol Cell Oncol
Ke ZY, Fu T, Wang XC, Ma X, Yin HH, Wang WX, Liu YJ, Liang AL.   +7 more
europepmc   +1 more source

The Natural Compound CalebinA Suppresses Gemcitabine Resistance and Tumor Progression by Inhibiting Angiogenesis and Invasion Through NF-κB Signaling in Pancreatic Cancer. [PDF]

Nutrients
Eguchi Y, Matsuo Y, Ishida M, Uehara Y, Sugita S, Denda Y, Nonoyama K, Murase H, Kato T, Saito K, Sato T, Sagawa H, Yamakawa Y, Ogawa R, Takahashi H, Mitsui A, Takiguchi S.   +16 more
europepmc   +1 more source

Targeting ALG3/FOXD1/BNIP3 Axis Prevents Mitophagy and Gemcitabine Resistance of Nasopharyngeal Carcinoma. [PDF]

Int J Biol Sci
Wang Z, Jin Y, He D, Zhu Y, Xiao M, Liu X, Cheng Y, Cao K.   +7 more
europepmc   +1 more source

O-GlcNAcylation with ubiquitination stabilizes METTL3 to promoting HMGB1 degradation to inhibit ferroptosis and enhance gemcitabine resistance in pancreatic cancer. [PDF]

Mol Med
Wang Q, Wei D, Li C, Yang X, Su K, Wang T, Zou R, Wang L, Cun D, Tang B, Wu T.   +10 more
europepmc   +1 more source

Bioinformatics-based screening of key genes associated with gemcitabine resistance in advanced pancreatic ductal adenocarcinoma. [PDF]

Transl Cancer Res
Hu K, Hasegawa K, Zhou G.
europepmc   +1 more source

Mathematical strategies for predicting resistant subpopulations from scRNAseq data of a PANC-1 3D tissue model: Insight into gemcitabine resistance and TGFB1-induced invasion and EMT. [PDF]

Comput Struct Biotechnol J
Caliskan A, Crouch SAW, Pereira JGN, Dandekar T, Dandekar G, Breitenbach T.   +5 more
europepmc   +1 more source

Promising molecular mechanisms responsible for gemcitabine resistance in cancer [PDF]

Genes and Diseases, 2015
Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance.
Yanfei Jia, Jingwu Xie
exaly   +4 more sources

Some of the next articles are maybe not open access.

Related searches:

Gemcitabine resistance in pancreatic ductal adenocarcinoma

Drug Resistance Updates, 2015
Pancreatic ductal adenocarcinoma (PDA) ranks fourth among cancer related deaths. The disappointing 5-year survival rate of below 5% stems from drug resistance to all known therapies, as well as from disease presentation at a late stage when PDA is already metastatic. Gemcitabine has been the cornerstone of PDA treatment in all stages of the disease for
Ziv Gil, Shorook Na'Ara
exaly   +3 more sources

Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine)

Drug Resistance Updates, 2002
The inherent or induced resistance of tumors to cytostatic agents is a major clinical problem. In this review, we summarize the pre-clinical mechanisms of acquired and inherent resistance to the fluorinated deoxycytidine analog gemcitabine (2',2'-difluorodeoxycytidine, dFdC, Gemzar((R))), which has proven activity in non-small cell lung carcinoma ...
Godefridus J Peters, Andries M Bergman
exaly   +3 more sources

Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer [PDF]

International Journal of Molecular Sciences, 2021
The overall five-year survival rate of pancreatic cancer has hardly changed in the past few decades (less than 10%) because of resistance to all known therapies, including chemotherapeutic drugs. In the past few decades, gemcitabine has been at the forefront of treatment for pancreatic ductal adenocarcinoma, but more strategies to combat drug ...
Qingcai Meng, Xianjun Yu, Jin Xu
exaly   +3 more sources